Studies in flies, worms, mice, and rats have made INDY a potential target that could be used in a clinical setting to alleviate some metabolic disorders such as NAFLD, Type 2 diabetes, insulin resistance, and even carcinogenesis. This evidence concerns the gene SLC13A5 and metabolic dysfunction-associated steatotic liver disease.